CoSTARS PLUS
Committed to your support

ENROLMENT FORM FOR DIABETES COSTARS PLUS: A PROGRAM TO SUPPORT PATIENTS ON APIDRA (INSULIN GLULISINE)

PHONE 1800 526 887 | FAX 1800 452 688 | EMAIL costars@remedyhealthcare.com.au

Please send the signed enrolment form via fax or email before or within five working days of your patient seeing the Credentialed Diabetes Educator (CDE). The CoSTARS® Plus program provides personalised additional health coaching support for your patient to achieve their prescribed titration goals.

PRESCRIBER DETAILS PLEASE NOTE: FOR COSTARS REIMBURSEMENT, PRESCRIBER CANNOT BE NOMINATED CDE/NP

Name:		Phone: ( )	
Practice:		Email:	
☐ GP	☐ Endocrinologist	☐ Nurse Practitioner	☐ Other

Prescription information

Patient current HbA1c:		Patient target HbA1c:	
☐ New to Apidra	☐ Continuing on Apidra	Duration of time on Apidra:	☐ YEARS ☐ MONTHS

Please choose the titration plan for Apidra:

☐ Plan A: Preset Titration Plan (As per guide on the following page)

☐ Plan B: Doctor Custom Plan (please specify PPBG target and titration regimen):

Please choose a CoSTARS® Plus support level: ☐ Telehealth support & CDE interaction OR ☐ Telehealth support only

Prescriber signature: MANDATORY FOR ENROLMENT	Print name:
	Date:

CDE/NP DETAILS

Name:	Clinic:

☐ I don't have a CDE (Remedy Healthcare can allocate a CDE/NP to the patient).
Note: if ticking this option, please attach a referral letter to this enrolment form.

PATIENT DETAILS

Name:		DOB:
Address:		Email:
		Phone (Preferred): ( )
	Postcode:	Phone (Alternate): ( )

☐ Yes, I have read and agree to the Privacy Statement set out below

☐ Yes, my healthcare provider has explained what is involved in the CoSTARS® Plus support program

☐ Yes, I consent to my Doctor being kept informed of my participation in the CoSTARS® Plus support program

☐ Yes, I consent to my CDE/NP being kept informed of my participation in the CoSTARS® Plus support program

☐ Yes, I consent to Sanofi using information that it collects as part of the CoSTARS® Plus support program such as PPBG, HbA1c and Apidra dose in a de-identified form (e.g. as part of publications or conference presentations).

By signing below I consent to enrolling into the Diabetes CoSTARS® Plus Program

Patients signature: MANDATORY FOR ENROLMENT	Print name:
	Date:

Thank you for your enrolment. You will be contacted by a CoSTARS® Plus Health Coach to commence the program.

Remedy HEALTHCARE

SANOFI DIABETES & CARDIOVASCULAR

CoSTARS PLUS
Committed to your support

MANAGE YOUR PATIENTS STARTING ON APIDRA®

THE COSTARS PLUS PATIENT SUPPORT PROGRAM

The CoSTARS Plus Support Program is for patients that have been prescribed Apidra®. As part of this program, your patient will receive:

- Up to three hours CDE interaction time
- Regular calls from the CoSTARS Health Coach based at Remedy Healthcare
- Tailored support to achieve their optimised insulin dose based on the prescribed titration plan
- Tailored support to achieve other health-related goals
- Unlimited inbound calls to CoSTARS Health Coach, available 9am-5pm AEST
- Welcome pack as required
- Additional dietitian support available through Remedy

TITRATION PLANS FOR PATIENTS

The goal of the CoSTARS® Plus support program is to improve glycaemic control in patients who require intensification of their basal insulin therapy with the addition of Apidra®. Please nominate one of the titration plans for your preferred Credentialed Diabetes Educator (CDE)/Nurse Practitioner (NP) to follow.

Prior to intensification with Apidra® please ensure the basal insulin your patient is on has been optimally titrated to achieve fasting blood glucose (FBG) targets.

Plan A: Preset Titration Plan

STEP 1
Identify the 'main meal'
Start Apidra® 4 units[3]



STEP 2
Titrate the Apidra® dose

STEP 3
Review A1c at 3 months[5,6]



STEP 4
Review the need for Apidra® at other mealtimes



OR

Plan B: Physician Custom Plan

STEP 1
PPBG target

Individualised PPBG target to be defined by Physician

STEP 2
Change in Apidra® dose

Customised titration regimen to be prescribed by Physician
(specify plan on application form)

SANOFI DIABETES & CARDIOVASCULAR

INSULINS CARRY A RISK OF HYPOGLYCAEMIA[7]

The risk of hypoglycaemia is increased if patients:

- accidentally use too much Apidra®
- have too much or unexpected exercise
- delay eating meals or snacks or eat too little food
- are ill

Prescribers are advised to provide guidance on 'hypo' identification and management to patients.

Desired blood glucose levels and the dosage of Apidra® should be individualised and determined based on the Physician's advice in accordance with the needs of the patient, especially those with a history of severe hypoglycaemia, a limited life expectancy, comorbidities or who are elderly.

Notes:
A1c = HbA1c, glycated haemoglobin PPBG = postprandial blood glucose FBG = fasting blood glucose
OAD = oral antidiabetic BGL = blood glucose level
Titration should be reviewed by a healthcare professional at each contact.
Patients need to be aware that a reduction in the carbohydrate content of their main meal will require a reduction in the dose of their mealtime insulin. Reduce the Apidra® dose and consider stopping sulphonylurea (if applicable) if hypoglycaemia occurs.

Privacy Statement: The CoSTARS® Plus Patient Support Program ("Program") is offered by Sanofi-Aventis Australia Pty Ltd ('Sanofi'). Sanofi complies with the Privacy Act 1988 (Cth) ('Privacy Act') to ensure that your personal information which includes health and sensitive information is protected. This Program is administered on behalf of Sanofi by Remedy Healthcare Group Pty Ltd ("Remedy"), a third party contactor for patient support services. Your personal information will be collected and stored by Remedy (or by an authorised third party) on behalf of Sanofi for the fulfilment of services to you as part of this Program.

Sanofi is committed to patient safety and carefully monitors potential adverse events relating to its products. In order to fulfil these legal obligations, Remedy (or any authorised third parties) will forward details of any adverse events including patient details to Sanofi. All personal information received by Sanofi is treated in confidence and in strict accordance with the Privacy Act. Sanofi may contact the treating physician in order to collect further information on the adverse event. Adverse event reports may also be forwarded to the relevant health authorities in de-identified format as per legal requirements.

Sanofi may also use information that it collects as part of the Program to advise healthcare professionals of patient experiences with Sanofi's product including via publication in medical journals and presentations at clinical meetings in a de-identified form. In addition your prescribing doctor and diabetes nurse professional contracted to the Program may have access to your health information collected during the Program for the purposes of managing your support whilst on the Program. For further information about Sanofi's Privacy Policy or to contact the Sanofi Privacy Officer, please visit www.sanofi.com.au/privacy

Other relevant information: Please note that Sanofi will pay a fee ranging from $40 to $240 (exc. GST) to the CDE/NP for the consultation(s) that form part of the program.

Contact Us: Should you wish to access, correct, delete, stop the process of your personal information or withdraw from the Program you can contact Remedy by email remedy@remedyhealthcare.com.au or in writing to Privacy Officer, Remedy Healthcare, PO Box 33356 Domain LPO Melbourne Vic 3004

The Diabetes CoSTARS® Plus Patient Support Program is designed to supplement (not replace) any existing General Practice Management Plan or Team Care Arrangement.

Prescriber's enrolling patients into the Diabetes CoSTARS® Plus Patient Support Program should ensure that hypoglycaemia, hyperglycaemic emergencies and sick day protocols are understood by patients and their carers, and that a knowledgeable resource person is contactable at all times (e.g. the patient's GP or associate, endocrinologist, diabetes resource centre).

CoSTARS PLUS
Committed to your support

PBS Information: Apidra® SoloStar®, Apidra® 3ml cartridges and Apidra® vial are listed on the PBS as a rapid acting insulin analogue for the treatment of type I and type 2 diabetes

Please review full Product Information before prescribing.
Full Product Information is available at
http://products.sanofi.com.au/aus_pi_apidra.pdf

Apidra® (insulin glulisine) Indications: For type 1 and type 2 diabetes mellitus patients (adults and children of 4 years or above) who require insulin for control of hyperglycaemia. **Contraindications:** Hypersensitivity to insulin glulisine or any excipient **Precautions:** Hypoglycaemia; hepatic, renal and visual impairment; lipodystrophy and other injection site reactions; antibody production; intercurrent conditions; not studied in children <4 years, pregnancy category B3, lactation. Apidra® may be mixed with NPH insulin; mixtures should not be administered intravenously. Instruct patient to check insulin label before each injection to avoid accidental mix-ups between insulins. **Interactions:** Oral antidiabetic agents; cardiovascular, analgaesic, anti-inflammatory, neurological, antipsychotic agents (see full PI); antibiotics; corticosteroids, other hormonal therapies (see full PI); diuretics; protease inhibitors; sympathomimetic agents; lithium; alcohol; sympatholytics including s-blockers; others, see full PI. **Side effects:** Hypoglycaemia; injection site reactions; others, see full PI. Dosage and Administration: Apidra® is equipotent to human insulin, with more rapid onset and shorter duration of action. Apidra® should be injected within 15 minutes before or immediately after a meal. Please review full Product Information before prescribing Apidra®. Date revised: 20 December 2010.

References: 1. National Evidence-Based Clinical Care Guidelines for Type 1 Diabetes in Children, Adolescents and Adults 2011. 2. National Institute for Health and Care Excellence Diabetes Pathways 2014. 3. Fulcher G, et al. AMJ 2010;3 (12):808-813. 4. Owens DR et al. Pract Diab Int 2009;26(2):70-77. 5. Nathan D et al. Diabetes Care 2009; 32(1):193-203. 6. Diabetes Australia/ RACGP. General Practice management of type 2 diabetes, 2014/15. 7. Apidra® Product Information, approved 26 August 2010.

Reference Document: PI, approved 26 August 2010. Date prepared September 2016 SAANZ.GLU.16.09.0353a

Remedy HEALTHCARE

SANOFI DIABETES & CARDIOVASCULAR